Azura Ophthalmics Presents Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian

TEL AVIV, Israel & MELBOURNE, Australia--(BUSINESS WIRE)--Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced that positive 3-month efficacy and safety results from its Phase 2b study of AZR-MD-0...

Related Keywords

California ,United States ,San Diego ,Melbourne ,Victoria ,Australia ,Americans ,Marc Gleeson ,Ashwin Agarwal ,Tara Mulloy ,Jenna Kane ,Azura Ophthalmics Ltd ,Twitter ,American Optometric Association ,Health Commerce ,Azura Primary Research ,Allergan ,Mcdonald ,International Workshop On Contact Lens Discomfort ,Ophthalmic Keratolytics ,Meibomian Gland Dysfunction ,Ophthalmology Innovation Summit ,Chief Executive Officer ,Meibomian Glands Yielding Liquid Secretion ,Ocular Surface Disease ,About Meibomian Gland ,Gland Dysfunction ,Dry Eye Disease ,Contact Lens ,Azura Ophthalmics ,Vis Sci ,Investigative Ophthalmology ,Visual Science ,Surface Disease Index ,All Rights ,Contact Lens Discomfort ,Contact Lens Interactions With ,Ocular Surface ,Invest Ophthalmol Vis ,